On April 18, 2023 the FDA responded to a January 2023 CAALM’s petition regarding mRNA vaccine labelling, they wrote in a letter [1] an alarming admission:
“FDA authorization and licensure standards for vaccines do not require demonstration of the prevention of infection or transmission…There is no requirement that the vaccine also prevents infection with the pathogen that can cause the disease or transmission of that pathogen to others…Similarly, a vaccine can meet the EUA standard without any evidence that the vaccine prevents infection or transmission.” [pg 11]
Moderna’s gene therapy products that are designed to treat an existing illness such as cancer can be labelled a “cancer vaccine“, allowing the product to get around regulatory barriers.